Immunosenescence and cancer

Critical Reviews in Oncogenesis

Volumn 18, Issue 6, 2013, Pages 489-513

  Fulop, Tamas ^a   Larbi, Anis ^b   Witkowski, Jacek M ^c   Kotb, Rami ^d   Hirokawa, Katsuiku ^e   Pawelec, Graham ^f  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b AGENCY FOR SCIENCE   (Singapore)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Aging; Cancer; Immunosenescence; Inflamm aging; Metabolic pathways

Indexed keywords

CD56 ANTIGEN; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 2; INTERLEUKIN 8; PROSTAGLANDIN E2;

ADAPTIVE IMMUNITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RISK; CANCER STAGING; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL AGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NEUTROPHIL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR MICROENVIRONMENT;

ADAPTIVE IMMUNITY; AGING; ANIMALS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; NEOPLASMS; TOLL-LIKE RECEPTORS;

EID: 84893109382     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.2013010597     Document Type: Article

References (212)

1. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6:715-27.
2. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-8.
3. Anisimov VN. Carcinogenesis and aging 20 years after: escaping horizon. Mech Ageing Dev. 2009;130:105-21.
4. Hoenicke L, Zender L. Immune surveillance of senescent cells-biological significance in cancer-and non-cancer pathologies. Carcinogenesis 2012;33:1123-1126.
5. Fulop T, Fortin C, Lesur O, Dupuis G, Kotb R, Lord JM, Larbi A. (2012) The innate immune system and aging: what is the contribution to immunose-nescence? Open Longevity Sci. 2012;6:121-32.
6. Fülöp T, Larbi A, Pawelec G. Human T Cell Aging and the impact of persistent viral infections. Front Immunol. 2013;4:271.
7. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012;23 Suppl 8:viii6-9.
8. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11-22.
9. Demaria S, Formenti SC. Role of T lymphocytes in tumor response to radiotherapy. Front Oncol. 2012;2:95.
10. Pawelec G. Hallmarks of human "immunosenescence": adaptation or dysregulation? Immun Ageing. 2012;9:15.
11. Fulop T, Larbi A, Kotb R, de Angelis F, Pawelec G. Aging, immunity, and cancer. Discov Med. 2011;11:537-50.
12. Fulop T, Kotb R, Fortin CF, Pawelec G, de Angelis F, Larbi A. Potential role of immunosenescence in cancer development. Ann N Y Acad Sci. 2010;1197:158-65.
13. Derhovanessian E, Solana R, Larbi A, Pawelec G. Immunity, ageing and cancer. Immun Ageing. 2008;5:11.
14. Mazzola P, Radhi S, Mirandola L, Annoni G, Jenkins M, Cobos E, Chiriva-Internati M. Aging, cancer, and cancer vaccines. Immun Ageing 2012;9:4.
15. Fan Y, Mao R, Yang J. NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 2013 Mar;4(3):176-85.
16. Wu Y, Antony S, Meitzler JL, Doroshow JH. Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer Lett. 2013 Aug 26. pii: S0304-3835(13)00589-2. doi: 10.1016/j. canlet.2013.08.014 [Epub ahead of print].
17. Gutkin DW, Shurin MR. Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunol Immunother. 2013 Oct 8 [Epub ahead of print].
18. Tili E, Michaille JJ, Croce CM. MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol Rev. 2013 May;253(1):167-84.
19. Catalán V, Gómez-Ambrosi J, Rodriguez A, Frühbeck G. Adipose tissue immunity and cancer. Front Physiol. 2013 Oct 2;4:275.
20. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008 Jun;8(6):467-77.
21. Ye XZ, Yu SC, Bian XW. Contribution of myeloid-derived suppressor cells to tumor-induced im-mune suppression, angiogenesis, invasion and metastasis. J Genet Genomics. 2010 Jul;37(7):423-30.
22. Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol. 2013 Sep;132(3):536-44.
23. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells-how did we miss them? Nat Rev Immunol. 2013 Feb;13(2):75-87.
24. Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyanishi M, Weissman IL. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci USA. 2013 Jul 2;110(27):11103-8.
25. Yanofsky VR, Mitsui H, Felsen D, Carucci JA. Understanding dendritic cells and their role in cutaneous carcinoma and cancer immunotherapy. Clin Dev Immunol. 2013;2013:624123.
26. Hao S, Andersen M, Yu H. Detection of immune suppressive neutrophils in peripheral blood samples of cancer patients. Am J Blood Res. 2013 Aug 19;3(3):239-45.
27. Ryan SO, Johnson JL, Cobb BA. Neutrophils confer T cell resistance to myeloid-derived suppressor cell-mediated suppression to promote chronic inflammation. J Immunol. 2013 May 15;190(10):5037-47.
28. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012, 23 Suppl 8:viii6-9.
29. Takahashi E, Kuranaga N, Satoh K, Habu Y, Shinomiya N, Asano T, Seki S, Hayakawa M. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16-CD56bright NK cells but also from CD16-CD56dim NK cells. Scand J Immunol. 2007;65:126-38.
30. Borrego F, Alonso MC, Galiani MD, Carracedo J, Ramirez R, Ostos B. NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol. 1999;34:253-65.
31. Chidrawar SM, Khan N, Chan YL, Nayak L, Moss PA. Ageing is associated with a decline in peripheral blood CD56bright NK cells. Immun Ageing. 2006, 3:10.
32. Krishnaraj R, Svanborg A. Preferential accumulation of mature NK cells during human immunosenescence. J Cell Biochem. 1992 Dec;50(4):386-91.
33. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003;101:2711-20.
34. Le Garff-Tavernier M, Beziat V, Decocq J, Siguret V, Gandjbakhch F, Pautas E, Debré P, Merle-Beral H, Vieillard V. Human NK cells display major phenotypic and functional changes over the life span. Aging Cell. 2010;9:527-35.
35. Ogata K, An E, Shioi Y, Nakamura K, Luo S, Yokose N, Minami S, Dan K. Association between natural killer cell activity and infection in immunologically normal elderly people. Clin Exp Immunol. 2001;124:392-7.
36. Mariani E, Pulsatelli L, Neri S, Dolzani P, Meneghetti A, Silvestri T. RANTES and MIP-1alpha production by T lymphocytes, monocytes and NK cells from nonagenarian subjects. Exp Gerontol. 2002;37:219-26.
37. Chiu BC, Martin BE, Stolberg VR, Chensue SW. The host environment is responsible for aging-related functional NK cell deficiency. J Immunol. 2013 Nov 1;191(9):4688-98.
38. Almeida-Oliveira A, Smith-Carvalho M, Porto LC, Cardoso-Oliveira, J, Ribeiro AS, Falcao RR. Age-related changes in natural killer cell receptors from childhood through old age. Human Immunology. 2011;72:319-29.
39. Romagnani C, Della Chiesa M, Kohler S, Moewes B, Radbruch A, Moretta L, Moretta A, Thiel A. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells Eur J Immunol. 2005;35:2452-8.
40. Lande R, Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses Ann N Y Acad Sci. 2010;1183:89-103.
41. Steinhagen F, McFarland AP, Rodriguez LG, Tewary P, Jarret A, Savan R, Klinman DM. IRF-5 and NF-κB p50 co-regulate IFN-β and IL-6 expression in TLR9-stimulated human plasmacytoid dendritic cells. Eur J Immunol. 2013 Jul;43(7):1896-906.
42. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells Cell. 2001,106:263-6.
43. Wong C, Goldstein DR. Impact of aging on antigen presentation cell function of dendritic cells. Curr Opin Immunol. 2013 Aug;25(4):535-41.
44. Peters T, Weiss JM, Sindrilaru A, Wang H, Oreshkova T, Wlaschek M, Maity P, Reimann J, Scharffetter-Kochanek K. Reactive oxygen intermediate-induced pathomechanisms contribute to immunosenescence, chronic inflammation and autoimmunity Mech Ageing Dev. 2009;130:564-87.
45. Stout-Delgado HW, Yang X, Walker WE, Tesar BM, Goldstein DR. Aging impairs IFN regulatory factor 7 up-regulation in plasmacytoid dendritic cells during TLR9 activation J Immunol. 2008;181: 6747-56.
46. Agrawal A, Agrawal S, Tay J, Gupta S. Biology of dendritic cells in aging. J Clin Immunol. 2008;28: 14-20.
47. Stout-Delgado HW, Du W, Shirali AC, Booth CJ, Goldstein DR. Aging promotes neutrophil-induced mortality by augmenting IL-17 production during viral infection Cell Host Microbe. 2009;6:446-56.
48. Agrawal A, Gupta S. Impact of aging on dendritic cell functions in humans Ageing Res Rev. 2011;10:336-45.
49. Della Bella S, Bierti L, Presicce P, Arienti R, Valenti M, Saresella M, Vergani C, Villa ML. Peripheral blood dendritic cells and monocytes are differently regulated in the elderly Clin Immunol. 2007;122:220-8.
50. Li G, Smithey MJ, Rudd BD, Nikolich-Žugich J. Age-associated alterations in CD8a+ dendritic cells impair CD8 T-cell expansion in response to an intracellular bacterium. Aging Cell. 2012;11:968-77.
51. Zhao J, Zhao J, Legge K, Perlman S. Age-related increases in PGD2 expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J Clin Invest. 2011;121:4921-30.
52. Grolleau-Julius A, Garg MR, Mo R, Stoolman LL, Yung RL. Effect of aging on bone marrow-derived murine CD11c+ CD4S CD8{alpha}-dendritic cell function. J Gerontol A Biol Sci Med Sci. 2006;61:1039-47.
53. Tesar BM, Walker WE, Unternaehrer J, Joshi NS, Chandele A, Haynes L. Murine myeloid dendritic cell-dependent toll-like receptor immunity is preserved with aging. Aging Cell. 2006;5:473-86.
54. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science. 2010;327:656-61.
55. Nyugen J, Agrawal S, Gollapudi S, Gupta S. Impaired functions of peripheral blood monocyte subpopulations in aged humans. J Clin Immunol. 2010;30:806-13.
56. Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population Immunology. 2007;120:435-46.
57. Panda A, Arjona A, Sapey E, Bai F, Fikrig E, Montgomery RR, Lord JM, Shaw AC. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol. 2009;30:325-33.
58. Crétel E, Veen I, Pierres A, Bongrand P, Gavazzi G. Immunosenescence and infections, myth or reality?. Med Mal Infect. 2010;40:307-18.
59. Agarwal S, Busse PJ. Innate and adaptive immunosenescence Ann Allergy Asthma Immunol. 2010;104:183-90.
60. Shaw AC, Joshi S, Greenwood H, Panda A, Lord JM. Aging of the innate system. Curr Opin Immunol. 2010;22:507-13.
61. Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S. Cutting edge: impaired Tolllike receptor expression and function in aging. J Immunol. 2002;169:4697-701.
62. van Duin D, Allore HG, Mohanty S, Ginter S, Newman FK, Belshe RB, Medzhitov R, Shaw AC. Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults. J Infect Dis. 2007;195:1590-7.
63. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, Cevenini E, Castellani GC, Salvioli S. Inflammaging and anti-inflamm aging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128:92-105.
64. Plowden J, Renshaw-Hoelscher M, Engleman C, Katz J, Sambhara S. Innate immunity in aging: impact on macrophage function. Aging Cell. 2004;3:161-7.
65. Ashcroft GS, Horan MA, Ferguson MW. Aging alters the inflammatory and endothelial cell adhesion molecule profiles during human cutaneous wound healing. Lab Invest. 1998;78:47-58.
66. Fulop T, Foris G, Worum I, Leovey A. Age-dependent changes of the Fc gamma-receptor-mediated functions of human monocytes. Int Arch Allergy Appl Immunol. 1984;74:76-79.
67. Wu D, Hayek MG, Meydani S. Vitamin E and macrophage cyclooxygenase regulation in the aged. J Nutr. 2001;131:382S-8S.
68. Gomez CR, Nomellini V, Faunce DE, Kovacs EJ. Innate immunity and aging. Exp Gerontol. 2008;43:718-28.
69. Pillay J, Kamp VM, van Hoffen E, Visser T, Tak T, Lammers JW, Ulfman LH, Leenen LP, Pickkers P, Koenderman L. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J Clin Invest. 2012 Jan 3;122(1):327-36.
70. Brackett CM, Muhitch JB, Evans SS, Gollnick SO. IL-17 Promotes neutrophil entry into tumor-draining lymph nodes following induction of sterile inflammation. J Immunol. 2013 Oct 15;191(8):4348-57.
71. Desai A, Grolleau-Julius A, Yung R. Leukocyte function in the aging immune system. J Leuk Biol. 2010;87:1001-9.
72. Wessels I, Jansen J, Rink L, Uciechowski P. Immunosenescence of polymorphonuclear neutrophils. Scientific World Journal. 2010;10:145-60.
73. Fortin CF, McDonald PP, Lesur O, Fülöp T Jr. Aging and neutrophils: there is still much to do. Rejuvenation Res. 2008;11:873-82.
74. Fulop T Jr, Foris G, Worum I, Leovey A. Age-dependent alterations of Fc gamma receptor-mediated effector functions of human polymorphonuclear leucocytes. Clin Exp Immunol. 1985;61:425-432.
75. Fulop T, Foris G, Worum I, Leovey A. Age-dependent changes of the Fc gamma-receptor-mediated functions of human monocytes. International Arch Allergy Appl Immunol. 1984;74:76-79.
76. Fulop T, Larbi A, Douziech N, Fortin C, Guérard KP, Lesur O, Khalil A, Dupuis G. Signal transduction and functional changes in neutrophils with aging. Aging Cell. 2004;3:217-26.
77. Wenisch C, Patruta A, Daxbock F, Krause R, Horl W. Effect of age on human neutrophil functions. J Leuk Biol. 2000;67:40-45.
78. Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V. Toll-like receptors control autophagy. EMBO J. 2008;27:1110-1121
79. Shaw AC, Panda A, Joshi SR, Qian F, Allore HG, Montgomery RR. Dysregulation of human Toll-like receptor function in aging. Ageing Res Rev. 2011;10:346-53.
80. Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara, S. Cutting edge: impaired Tolllike receptor expression and function in aging. J Immunol. 2002;169:4697-701.
81. van Duin D, Shaw AC. Toll-like receptors in older adults. J Am Geriatr Soc. 2007;55:1438-44.
82. Mankan AK, Dau T, Jenne D, Hornung V. The NLRP3/ASC/caspase-1 axis regulates IL-1β processing in neutrophils. Eur J Immunol. 2012;42: 710-5.
83. Wen H, Miao EA, Ting JP. Mechanisms of NODlike receptor-associated inflammasome activation. Immunity. 2013 Sep 19;39(3):432-41.
84. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373-84.
85. Wu S, Metcalf JP, Wu W. Innate immune response to influenza virus. Curr Opin Infect Dis. 2011;24: 235-40.
86. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol. 2011;29:447-91.
87. Ostuni R, Zanoni I, Granucci F. Deciphering the complexity of Toll-like receptor signaling. Cell Mol Life Sci. 2010;67:4109-34.
88. Kawai T, Akira S. Signaling to NF-kappaB by Tolllike receptors. Trends Mol Med. 2007;13:460-9.
89. Mariani E, Pulsatelli L, Neri S, Dolzani P, Meneghetti A, Silvestri T. RANTES and MIP-1alpha production by T lymphocytes, monocytes and NK cells from nonagenarian subjects. Exp Gerontol. 2002;37:219-26.
90. Puga I, Cols M, Barra CM, He B, Cassis L, Gentile M, Comerma L, Chorny A, Shan M, Xu W, Magri G, Knowles DM, Tam W, Chiu A, Bussel JB, Serrano S, Lorente JA, Bellosillo B, Lloreta J, Juanpere N, Alameda F, Baró T, de Heredia CD, Torán N, Català A, Torrebadell M, Fortuny C, Cusí V, Carreras C, Diaz GA, Blander JM, Farber CM, Silvestri G, Cunningham-Rundles C, Calvillo M, Dufour C, Notarangelo LD, Lougaris V, Plebani A, Casanova JL, Ganal SC, Diefenbach A, Aróstegui JI, Juan M, Yagüe J, Mahlaoui N, Donadieu J, Chen K, Cerutti A. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol. 2011;13:170-80.
91. Verschoor CP, Johnstone J, Millar J, Dorrington MG, Habibagahi M, Lelic A, Loeb M, Bramson JL, Bowdish DM. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol. 2013 Apr;93(4):633-7.
92. Bowdish DM. Myeloid-derived suppressor cells, age and cancer. Oncoimmunology. 2013 Jul 1;2(7):e24754.
93. Lechner MG, Megiel C, Russell SM, Bingham B, Arger N, Woo T, Epstein AL. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med. 2011 Jun 9;9:90.
94. Zou H, Stoppani E, Volonte D, Galbiati F. Caveolin-1, cellular senescence and age-related diseases. Mech Ageing Dev. 2011 Nov-Dec;132(11-12):533-42.
95. Sawant A, Schafer CC, Jin TH, Zmijewski J, Tse HM, Roth J, Sun Z, Siegal GP, Thannickal VJ, Grant SC, Ponnazhagan S, Deshane JS. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. Cancer Res. 2013 Oct 4 [Epub ahead of print].
96. Pawelec G, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, Wikby A. Human immunosenescence: is it infectious?. Immunol Rev. 2005;205:257-68.
97. Pellicanò M, Larbi A, Goldeck D, Colonna-Romano G, Buffa S, Bulati M, Rubino G, Iemolo F, Candore G, Caruso C, Derhovanessian E, Pawelec G. Immune profiling of Alzheimer patients. J Neuroimmunol. 2012;242:52-9.
98. Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian E, Goldeck D, Fulop T. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J Alzheimers Dis. 2009;17:91-103.
99. Solana R, Tarazona R, Aiello AE, Akbar AN, Appay V, Beswick M, Bosch JA, Campos C, Cantisán S, Cicin-Sain L, Derhovanessian E, Ferrando-Martinez S, Frasca D, Fulöp T, Govind S, Grubeck-Loebenstein B, Hill A, Hurme M, Kern F, Larbi A, López-Botet M, Maier AB, McElhaney JE, Moss P, Naumova E, Nikolich-Zugich J, Pera A, Rector JL, Riddell N, Sanchez-Correa B, Sansoni P, Sauce D, van Lier R, Wang GC, Wills MR, Zieliński M, Pawelec G. CMV and Immunosenescence: from basics to clinics. Immun Ageing. 2012;9:23.
100. Poschke I, De Boniface J, Mao Y, Kiessling R. Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients. Int J Cancer. 2012;131:1611-20.
101. Hotta K, Sho M, Fujimoto K, Shimada K, Yamato I, Anai S, Konishi N, Hirao Y, Nonomura K, Nakajima, Y. Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. Br J Cancer. 2011;105:1191-6.
102. Henson SM, Riddell NE, Akbar AN. Properties of end-stage human T cells defined by CD45RA reexpression. Curr Opin Immunol. 2012;24:476-81.
103. Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013 Apr;25(2):214-21.
104. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007 Oct;27(4):670-84.
105. Chou JP, Effros RB. T cell replicative senescence in human aging. Curr Pharm Des. 2013; 19(9): 1680-98.
106. Di Mitri D, Azevedo RI, Henson SM, Libri V, Riddell NE, Macaulay R, Kipling D, Soares MV, Battistini L, Akbar AN. Reversible senescence in human CD4+CD45RA+CD27-memory T cells. J Immunol. 2011;187:2093-100.
107. Li C, Beavis P, Palfreeman AC, Amjadi P, Kennedy A, Brennan FM. Activation of p38 mitogen-activated protein kinase is critical step for acquisition of effector function in cytokine-activated T cells, but acts as a negative regulator in T cells activated through the T-cell receptor. Immunology. 2011;132:104-10.
108. Rincón M, Pedraza-Alva G. JNK and p38 MAP kinases in CD4+ and CD8+ T cells. Immunol Rev. 2003;192:131-42.
109. Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W, Schickler M, Rotem-Yehudar R, Kufe D, Avigan D. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011;34:409-18.
110. Robert C, Thomas L, Bondarenko I, O'Day S, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26.
111. Simeone E, Ascierto PA. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol. 2012;9:241-7.
112. Wikby A, Ferguson F, Forsey R, Thompson J, Strindhal J, Lofgren S, Nilsson BO, Ernerudh J, Pawelec G, Johansson B. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci. 2005;60:556-65.
113. Wikby A, Månsson IA, Johansson B, Strindhall J, Nilsson SE. The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20-100 years of age. Biogerontology. 2008;9:299-308.
114. Wikby A, Johansson B, Olsson J, Löfgren S, Nilsson BO, Ferguson F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol. 2002;37:445-53.
115. Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Ferguson FG. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev. 2000;121:187-201.
116. Pawelec G, McElhaney JE, Aiello AE, Derhovanessian E. The impact of CMV infection on survival in older humans. Curr Opin Immunol. 2012;24:507-11.
117. Derhovanessian E, Maier AB, Hähnel K, Zelba H, de Craen AJ, Roelofs H, Slagboom EP, Westendorp RG, Pawelec G. Lower proportion of naïve peripheral CD8+ T cells and an unopposed pro-inflammatory response to human Cytomegalovirus proteins in vitro are associated with longer survival in very elderly people. Age (Dordr). 2013 Aug;35(4):1387-99. doi: 10.1007/s11357-012-9425-7. Epub 2012 Jun 4.
118. Bartlett DB, Firth CM, Phillips AC, Moss P, Baylis D, Syddall H, Sayer AA, Cooper C, Lord JM. The age-related increase in low-grade systemic inflammation (inflammaging) is not driven by cytomegalovirus infection. Aging Cell. 2012;11:912-5.
119. Griffiths HR, Dunston CR, Bennett SJ, Grant MM, Phillips DC, Kitas, GD. Free radicals and redox signalling in T-cells during chronic inflammation and ageing. Biochem Soc Trans. 2011;39:1273-8.
120. Larbi A, Cabreiro F, Zelba H, Marthandan S, Combet E, Friguet B, Petropoulos I, Barnett Y, Pawelec G. Reduced oxygen tension results in reduced human T cell proliferation and increased intracellular oxidative damage and susceptibility to apoptosis upon activation. Free Radic Biol Med. 2010;48:26-34.
121. Larbi A, Dupuis G, Khalil A, Douziech N, Fortin C, Fülöp T Jr. Differential role of lipid rafts in the functions of CD4+ and CD8+ human T lymphocytes with aging. Cell Signal. 2006;18:1017-30.
122. Larbi A, Douziech N, Dupuis G, Khalil A, Pelletier H, Guerard KP, Fulop T Jr. Age associated alterations in the recruitment of signal transduction proteins to lipid rafts in human T lymphocytes. J Leuk Biol. 2004;75:373-381.
123. Larbi A, Dupuis G, Douziech N, Fulop T. Low-grade inflammation with aging has consequences for T-lymphocyte signaling. Ann N Y Acad Sci. 2004;1030:125-33.
124. Salmond RJ, Filby A, Qureshi I, Caserta S, Zamoyska R. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol. Rev. 2009;228:9-22.
125. Schoenborn JR, Tan YX, Zhang C, Shokat KM, Weiss A. Feedback circuits monitor and adjust basal Lck-dependent events in T cell receptor signaling. Science Signal. 2011;4:ra59.
126. Goronzy JJ, Li G, Yu M, Weyand CM. Signaling pathways in aged T cells-A reflection of T cell differentiation, cell senescence and host environment. Semin Immunol. 2012;24:365-72.
127. Larbi A, Pawelec G, Wong SC, Goldeck D, Tai JJ, Fülöp T. Impact of age on T cell signaling: A general defect or specific alterations?. Ageing Res Rev. 2011;10:370-8.
128. Xu X, Ye L, Araki K, Ahmed R. mTOR, linking metabolism and immunity. Semin Immunol. 2012 Dec;24(6):429-35.
129. Yang K, Chi H. mTOR and metabolic pathways in T cell quiescence and functional activation. Semin Immunol. 2012 Dec;24(6):421-8.
130. Heikamp EB, Powell JD. Sensing the immune microenvironment to coordinate T cell metabolism, differentiation and function. Semin Immunol. 2012 Dec;24(6):414-20.
131. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012 Apr 13;149(2):274-93.
132. Cornu M, Albert V, Hall MN. mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev. 2013 Feb;23(1):53-62.
133. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009 May;9(5):324-37.
134. Barbi J, Pardoll D, Pan F. Metabolic control of the Treg/ Th17 axis. Immunol Rev. 2013 Mar;252(1):52-77.
135. Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol. 2012 Apr 20;12(5):325-38.
136. Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, Xiao B, Worley PF, Powell JD. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol. 2011 Apr;12(4):295-303.
137. Benhamron S, Tirosh B. Direct activation of mTOR in B lymphocytes confers impairment in B-cell maturation and loss of marginal zone B cells. Eur J Immunol. 2011 Aug;41(8):2390-6.
138. Araki K, Youngblood B, Ahmed R. The role of mTOR in memory CD8 T-cell differentiation. Immunol Rev. 2010 May;235(1):234-43.
139. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009 Jul 2;460(7251):108-12.
140. Jones RG, Thompson CB. Revving the engine: signal transduction fuels T cell activation. Immunity. 2007 Aug;27(2):173-8.
141. Pearce EL. Metabolism in T cell activation and differentiation. Curr Opin Immunol. 2010 Jun;22(3):314-20.
142. Yang K, Neale G, Green DR, He W, Chi H. The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. Nat. Immunol. 2011 Jul 17;12(9):888-97.
143. Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol. 2011 Dec;23(6):744-55.
144. Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am. 2013 Oct;22(4):641-64.
145. Gao W, Thompson L, Zhou Q, Putheti P, Fahmy TM, Strom TB, Metcalfe SM. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle. 2009 May 1;8(9):1444-50.
146. Heinbokel T, Elkhal A, Liu G, Edtinger K, Tullius SG. Immunosenescence and organ transplantation. Transplant Rev (Orlando). 2013;27:65-75.
147. Riley RL, Blomberg BB, Frasca D. B cells, E2A and aging. Immunol Rev. 2005;205:30-47.
148. Gibson KL, Wu YC, Barnett Y, Duggan O, Vaughan R, Kondeatis E, Nilsson BO, Wikby A, Kipling D, Dunn-Walters DK. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell. 2009;8:18-25.
149. Colonna-Romano G, Bulati M, Aquino A, Scialabba G, Candore G, Lio D, Motta M, Malaguarnera M, Caruso C. Mech Ageing Dev. 2003;124:389-93.
150. Lazuardi L, Jenewein B, Wolf AM, Pfister G, Tzankov A, Grubeck-Loebenstein B. Age-related loss of naïve T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology. 2005;114:37-43.
151. Bryl E, Vallejo AN, Matteson EL, Witkowski JM, Weyand CM, Goronzy JJ. Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum. 2005;52:2996-3003.
152. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87-91.
153. Akulian JA, Pipeling MR, John ER, Orens JB, Lechtzin N, McDyer JF. High-quality CMV-specific CD4(+) memory is enriched in the lung allograft and is associated with mucosal viral control. Am J Transplant. 2012;Sep 27: doi: 10.1111/j.1600-6143.2012.04282.x.
154. Brüning CA, Prigol M, Luchese C, Jesse CR, Duarte MM, Roman SS, Nogueira CW. Protective effect of diphenyl diselenide on ischemia and reperfusion-induced cerebral injury: involvement of oxidative stress and pro-inflammatory cytokines. Neurochem Res. 2012;37:2249-58.
155. Vasto S, Carruba G, Lio D, Colonna-Romano G, Di Bona D, Candore G, Caruso C. Inflammation, ageing and cancer. Mech Ageing Dev. 2009;130: 40-5.
156. Chung HY, Cesari M, Anton S. Marzetti E, Giovannini S, Seo AY, Carter C, Yu BP, Leeuwenburgh C. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Res Rev. 2009;8:18-30.
157. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel, R. Page M, Kaltschmidt, C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996;97:1715-22.
158. Macaulay R, Akbar AN, Henson SM. The role of the T cell in age-related inflammation. Age (Dordr). 2013 Jun;35(3):563-72. doi: 10.1007/s11357-012-9381-2. Epub 2012 Jan 15. Review.
159. Novosyadlyy R, Leroith D. Insulin-like growth factors and insulin: at the crossroad between tumor development and longevity. J Gerontol A Biol Sci Med Sci. 2012;67:640-51.
160. Harman D. About "Origin and evolution of the free radical theory of aging: a brief personal history, 1954-2009". Biogerontology. 2009;10:783.
161. Sosa V, Moliné T, Somoza R, Paciucci R, Kondoh H, LLeonart ME. Oxidative stress and cancer: an overview. Ageing Res Rev. 2013;12:376-90.
162. Lisanti MP, Martinez-Outschoorn UE, Lin Z, Pavlides S, Whitaker-Menezes D, Pestell RG, Howell A, Sotgia F. Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs "fertilizer". Cell Cycle. 2011;10:2440-9.
163. Cannizzo ES, Clement CC, Sahu R, Follo C, Santambrogio L. Oxidative stress, inflammaging and immunosenescence. J Proteomics. 2011;74:2313-23.
164. De la Fuente M, Miquel J. An update of the oxidation-inflammation theory of aging: the involvement of the immune system in oxi-inflamm-aging. Curr Pharm Des. 2009;15:3003-26.
165. Mammucari C, Rizzuto R. Signaling pathways in mitochondrial dysfunction and aging. Mech. Age Dev. 2010;131:536-43.
166. Bellot GL, Liu D, Pervaiz S. ROS, autophagy, mitochondria and cancer: Ras the hidden master? Mitochondrion. 2013;13:155-162.
167. Baraibar MA, Ladouce R, Friguet B. Proteomic quantification and identification of carbonylated proteins upon oxidative stress and during cellular aging. J Proteomics. 2013 May 18. doi: pii: S1874-3919(13)00249-2. 10.1016/j.jprot.2013.05.008.
168. Baraibar MA, Liu L, Ahmed EK, Friguet B. Protein oxidative damage at the crossroads of cellular senescence, aging, and age-related diseases. Oxid Med Cell Longev. 2012;2012:919832.
169. Mishto M, Santoro A, Bellavista E, Bonafé M, Monti D, Franceschi C. Immunoproteasomes and immunosenescence. Ageing Res Rev. 2003 Oct;2(4):419-32.
170. Friguet B. Proteasome activity and immunosenescence. In: Fulop T, Franceschi C, Hirokawa K, Pawelec G, editors. Handbook on Immunosenescence. Amsterdam: Springer; 2009. p.729-52.
171. Nyström T, Yang J, Molin M. Peroxiredoxins, gerontogenes linking aging to genome instability and cancer. Genes Dev. 2012;26:2001-8.
172. Sprung CN, Ivashkevich A, Forrester HB, Redon CE, Georgakilas A, Martin OA. Oxidative DNA damage caused by inflammation may link to stress-induced non-targeted effects. Cancer Lett. 2013 Sep 14. doi: pii: S0304-3835(13)00661-7.
173. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009 Jul;10(7):718-26.
174. Redon CE, Dickey JS, Nakamura AJ, Kareva IG, Naf D, Nowsheen S, Kryston TB, Bonner WM, Georgakilas AG, Sedelnikova OA. Tumors induce complex DNA damage in distant proliferative tissues in vivo. Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):17992-7.
175. Duechler M, Peczek L, Zuk K, Zalesna I, Jeziorski A, Czyz M. The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes. Immunobiology. 2013 Sep 8. doi: pii: S0171-2985(13)00166-6.
176. Klein-Goldberg A, Maman S, Witz IP. The role played by the microenvironment in site-specific metastasis. Cancer Lett. 2013 Aug 27. pii: S0304-3835(13)00604-6. doi: 10.1016/j.canlet.2013.08.029 [Epub ahead of print].
177. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M. Tumour biology: senescence in premalignant tumours. Nature. 2005 Aug 4;436(7051):642.
178. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dörken B, Jenuwein T, Schmitt CA. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005 Aug 4;436(7051):660-5.
179. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 2005 Feb 25;120(4):513-22.
180. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007 Feb 8;445(7128):656-60.
181. Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 2006 Jan 15;66(2):794-802.
182. Douziech N, Seres I, Larbi A, Szikszay E, Roy PM, Arcand M, Dupuis G, Fulop T Jr. Modulation of human lymphocyte proliferative response with aging. Exp Gerontol. 2002;37:369-87.
183. Hybertson BM, Gan B, Rose SK, McCord JM. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol Aspects Med. 2011;32:234-246.
184. Burgdorf S, Kautz A, Böhnert V, Knolle PA, Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science. 2007 Apr 27;316(5824):612-6.
185. Pan XD, Mao YQ, Zhu LJ, Li J, Xie Y, Wang L, Zhang GB. Changes of regulatory T cells and FoxP3 gene expression in the aging process and its relationship with lung tumors in humans and mice. Chin Med J (Engl). 2012 Jun;125(11):2004-11.
186. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006 Apr;6(4):295-307.
187. Fessler J, Ficjan A, Duftner C, Dejaco C. The impact of aging on regulatory T-cells. Front Immunol. 2013;4:231.
188. Falci C, Gianesin K, Sergi G, Giunco S, De Ronch I, Valpione S, Soldà C, Fiduccia P, Lonardi S, Zanchetta M, Keppel S, Brunello A, Zafferri V, Manzato E, De Rossi A, Zagonel V. Immune senescence and cancer in elderly patients: Results from an exploratory study. Exp Gerontol. 2013 Oct 10;48(12):1436-42.
189. De Angulo A, Faris R, Cavazos D, Jolly C, Daniel B, DeGraffenried L. Age-related alterations in T-lymphocytes modulate key pathways in prostate tumorigenesis. Prostate. 2013 Jun;73(8):855-64.
190. Gruber IV, El Yousfi S, Durr-Storzer S, Wallwiener D, Solomayer EF, Fehm T. Down-regulation of CD28, TCRzeta (ζ) and up-regulation of FAS in peripheral cytotoxic T cells of primary breast cancer patients. Anticancer Res. 2008;28(2A):779-84.
191. Gruber I, Landenberger N, Staebler A, Hahn M, Wallwiener D, Fehm T. Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer. Anticancer Res. 2013 May;33(5):2233-8.
192. Luca PJ, Negishi I, Nakayama K, Fields LE, Loh DY. Naive CD28-deficient T-cells can initiate but not sustain an in vitro antigen-specific immune response. J Immunol. 1995;154(11):5757-68.
193. Gudmundsdottir H, Wells AD, Turka LA. Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: Effector function is linked to proliferation capacity. J Immunol. 1999;162(9):5212-23.
194. Keene JA, Forman J. Helper activity is required for the in vivo generation of cytotoxic T-lymphocytes. J Exp Med. 1982;155(3):768-82.
195. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger. CD4+ T-cells are required for secondary expansion and memory in CD8+ T-lymphocytes. Nature. 2003;421(6925):852-6.
196. Shedlock DJ, Shen H. Requirement for CD4 T-cell help in generating functional CD8 T-cell memory. Science. 2003;300(5617):337-9.
197. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781-91.
198. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005;23(7):1420-30.
199. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des. 2012;18:3831-52.
200. Ye J, Ma C, Hsueh EC, Eickhoff CS, Zhang Y, Varvares MA, Hoft DF, Peng G. Tumor-derived γδ regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J Immunol. 2013;190:2403-14.
201. Wayteck L, Breckpot K, Demeester J, De Smedt SC, Raemdonck K. A personalized view on cancer immunotherapy. Cancer Lett. 2013 Sep 17. pii: S0304-3835(13)00670-8. doi: 10.1016/j.canlet.2013.09.016. [Epub ahead of print].
202. Sun SY. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett. 2013 Oct 28;340(1):1-8.
203. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012 Apr;24(2):207-12.
204. Jacobsen ED. Restoring antitumor immunity via PD-1 blockade after autologous stem-cell transplantation for diffuse large B-cell lymphoma. J Clin Oncol. 2013 Oct 14 [Epub ahead of print].
205. Merelli B, Massi D, Cattaneo L, Mandalà M. Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol. 2013 Aug 28. doi: pii: S1040-8428(13)00179-0. 10.1016/j.critrevonc.2013.08.002 [Epub ahead of print].
206. Hanna MG Jr. Cancer vaccines: are we there yet?. Crit Rev Oncol Hematol. 2014 Jan;89(1):140-65. doi: 10.1016/j.critrevonc.2013.08.002. Epub 2013 Aug 28.
207. Flinsenberg TW, Compeer EB, Boelens JJ, Boes M. Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention. Clin Exp Immunol. 2011;165:8-18.
208. Ma Y, Aymeric L, Locher C, Kroemer G, Zitvogel L. The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol. 2011;23:146-52.
209. Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology. 2013 Aug 1;2(8):e25961.
210. Criscitiello C, Curigliano G. Immunotherapeutics for breast cancer. Curr Opin Oncol. 2013 Nov;25(6):602-8.
211. Gogas H, Polyzos A, Kirkwood J. Immunotherapy for advanced melanoma: fulfilling the promise. Cancer Treat Rev. 2013 Dec;39(8):879-85.
212. Glebova K, Veiko N, Kostyuk S, Izhevskaya V, Baranova A. Oxidized extracellular DNA as a stress signal that may modify response to anticancer therapy. Cancer Lett. 2013 Sep 14. doi: pii: S0304-3835(13)00658-7. 10.1016/j.canlet.2013.09.005 [Epub ahead of print].